NCT02386566View on ClinicalTrials.gov

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

March 20, 2015

Primary Completion Date

January 28, 2018

Study Completion Date

January 28, 2018

Conditions
Multiple Sclerosis
Interventions
DRUG

natalizumab

As described in the treatment arm

Trial Locations (7)

Unknown

Research Site, Aarau

Research Site, Basel

Research Site, Bern

Research site - private practice, Lucerne

Research Site, Lugano

Research Site, Wohlen

Research Site, Zurich

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT02386566 - Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab | Biotech Hunter | Biotech Hunter